G&S Capital’s Celgene Corp CELG Stock Holding History

G&S Capital’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-600	Closed	-$55K	–	257
2019 Q2	$55K	Sell	600 -50	-8%	-$4.75K	0.03%	124
2019 Q1	$61K	Hold	650	–	–	0.04%	114
2018 Q4	$42K	Hold	650	–	–	0.04%	103
2018 Q3	$58K	Hold	650	–	–	0.04%	118
2018 Q2	$52K	Hold	650	–	–	0.04%	114
2018 Q1	$58K	Hold	650	–	–	0.05%	103
2017 Q4	$68K	Buy	+650	New	+$73.3K	0.05%	118

Other funds holding CELG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

G&S Capital's CELG Position: Q3 2019 in Review

G&S Capital sold out of Celgene Corp (CELG) in Q3 2019, closing a stake of 600 shares — an estimated $55K sold.

G&S Capital first reported a position in CELG in Q4 2017 and held it in 7 quarters. The position peaked at $68K in Q4 2017. 1,245 funds tracked by Wall St. Rank hold CELG as of Q3 2019.

G&S Capital reported no remaining Celgene Corp position as of Q3 2019 after selling out during the quarter.
G&S Capital sold 600 Celgene Corp shares in Q3 2019, an estimated $55K.
G&S Capital first reported a position in Celgene Corp in Q4 2017 and held it in 7 quarters.
G&S Capital's Celgene Corp position peaked at $68K in Q4 2017.
1,245 funds tracked by Wall St. Rank held Celgene Corp as of Q3 2019.

Based on G&S Capital's 13F filing for Q3 2019, filed 17 Oct 2019.